These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 21697653)
21. Macrophage regulation of tumor responses to anticancer therapies. De Palma M; Lewis CE Cancer Cell; 2013 Mar; 23(3):277-86. PubMed ID: 23518347 [TBL] [Abstract][Full Text] [Related]
22. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Grothey A; Ellis LM Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556 [TBL] [Abstract][Full Text] [Related]
23. Targeted therapies for solid tumors: current status and future perspectives. Stoffel A BioDrugs; 2010 Oct; 24(5):303-16. PubMed ID: 20649180 [TBL] [Abstract][Full Text] [Related]
25. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. Kim DG; Jin Y; Jin J; Yang H; Joo KM; Lee WS; Shim SR; Kim SW; Yoo J; Lee SH; Yoo JS; Nam DH MAbs; 2015; 7(6):1195-204. PubMed ID: 26325365 [TBL] [Abstract][Full Text] [Related]
26. Anti-Angiogenics: Current Situation and Future Perspectives. Zirlik K; Duyster J Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226 [TBL] [Abstract][Full Text] [Related]
27. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. Horn L; Sandler A Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S68-73. PubMed ID: 17382027 [TBL] [Abstract][Full Text] [Related]
28. [Role of angiogenesis inhibitors in the treatment of colorectal cancer]. Bodoky G Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870 [TBL] [Abstract][Full Text] [Related]
29. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621 [TBL] [Abstract][Full Text] [Related]
30. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor. Adjei AA Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028 [TBL] [Abstract][Full Text] [Related]
31. [Advances of VEGF related molecular promoting tumor angiogenesis and targeting therapy]. Guo ZY; Cao BL Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):282-4. PubMed ID: 20654135 [No Abstract] [Full Text] [Related]
32. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Hack SP; Zhu AX; Wang Y Front Immunol; 2020; 11():598877. PubMed ID: 33250900 [TBL] [Abstract][Full Text] [Related]
33. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility. Close A Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926 [TBL] [Abstract][Full Text] [Related]
36. Recent advances in anti-angiogenic therapy of cancer. Samant RS; Shevde LA Oncotarget; 2011 Mar; 2(3):122-34. PubMed ID: 21399234 [TBL] [Abstract][Full Text] [Related]
37. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Leite de Oliveira R; Hamm A; Mazzone M Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050 [TBL] [Abstract][Full Text] [Related]
38. The role of antiangiogenesis therapy: bevacizumab and beyond. Cortés-Funes H Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449 [TBL] [Abstract][Full Text] [Related]
39. The role of angiogenesis inhibitors in prostate cancer. Aragon-Ching JB; Dahut WL Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479 [TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic agents in breast cancer. Salter JT; Miller KD Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]